NasdaqCM - Delayed Quote USD

MiNK Therapeutics, Inc. (INKT)

0.9275 +0.0563 (+6.46%)
At close: April 26 at 4:00 PM EDT
0.9748 +0.05 (+5.10%)
After hours: April 26 at 7:22 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for INKT

Recent News: INKT

View More
This MiNK Therapeutics Insider Increased Their Holding In The Last Year

This MiNK Therapeutics Insider Increased Their Holding In The Last Year
Simply Wall St. 15 days ago
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
GlobeNewswire 18 days ago
All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy

All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy
Zacks last month
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript
Insider Monkey last month

Q4 2023 Mink Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents last month
MiNK Reports Fourth Quarter and Year-End 2023 Results

MiNK Reports Fourth Quarter and Year-End 2023 Results
GlobeNewswire last month
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
GlobeNewswire last month
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
GlobeNewswire last month
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
GlobeNewswire 2 months ago
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
GlobeNewswire 2 months ago
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
GlobeNewswire 2 months ago
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
GlobeNewswire 4 months ago
View More

Related Tickers

AGEN Agenus Inc.
11.69
+40.84%
 
PTIX Protagenic Therapeutics, Inc.
1.3850
-4.48%
 
IKT Inhibikase Therapeutics, Inc.
1.7100
-8.06%
 
MBIO Mustang Bio, Inc.
0.3161
-11.58%
 
LIXT Lixte Biotechnology Holdings, Inc.
3.2600
+0.31%
 
MGNX MacroGenics, Inc.
14.56
+1.32%
 
XLO Xilio Therapeutics, Inc.
1.0900
+7.92%
 
ATHE Alterity Therapeutics Limited
2.5100
+9.61%
 
CTMX CytomX Therapeutics, Inc.
1.5900
-0.62%
 
ALZN Alzamend Neuro, Inc.
0.7195
-0.90%